Ovarian dysfunction in patients with gestational trophoblastic neoplasia treated with short intensive courses of etoposide (VP-16-213)

✍ Scribed by Yew C. Choo; Steven Y. W. Chan; Leng C. Wong; Ho K. Ma

• Publisher: John Wiley and Sons
• Year: 1985
• Tongue: English
• Weight: 417 KB
• Volume: 55
• Category: Article
• ISSN: 0008-543X
• DOI: 10.1002/1097-0142(19850515)55:10<2348::aid-cncr2820551009>3.0.co;2-i

✦ Synopsis

The effect of oral Etoposide (VP-16-213) on the ovarian function in 22 patients with residual gestational trophoblastic disease was studied by serial weekly measurement of serum follicle stimulating hormone (FSH), 17B-estradiol (El), progesterone (P) and prolactin (PRL), and monitoring of the menstrual patterns during and after drug treatment. Multiple courses of VP-16-213 at a dosage of 200 mg/m2 X 5 days were given 1 week apart. Following an average dose of 5.0 gm, five young patients developed transient ovarian failure for a mean period of 2.4 months and two elderly patients developed permanent ovarian failure (total incidence, 7/22, 31.88) as evidenced by hypergonadotropic, hypoestrogenic amenorrhea. In addition, two patients each developed anovulatory cycles and hypomenorrhea. VP-16-213 should therefore be regarded a potent gonadotoxic drug and these hitherto unreported side effects should be recognized when the drug is used in menstruating females.

Cancer 55: